O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 484-490

  Wu, Pei Fang ^a   Kuo, Kuan Ting ^b   Kuo, Lu Ting ^b   Lin, Yi Ting ^b   Lee, Wei Chung ^b   Lu, Yen Shen ^b   Yang, Chih Hsin ^b   Wu, Ruey Meei ^b   Tu, Yong Kwang ^b   Tasi, Jui Chang ^b   Tseng, Ham Min ^b   Tseng, Sheng Hong ^b   Cheng, Ann Lii ^b   Lin, Ching Hung ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Brain metastasis; Immunohistochemistry; MGMT; O6 Methylguanine DNA methyltransferase

Indexed keywords

DOCETAXEL; EPIRUBICIN; ETOPOSIDE; GEFITINIB; GEMCITABINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NAVELBINE; PLATINUM DERIVATIVE; ALKYLATING AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TEMOZOLOMIDE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STEREOTACTIC RADIOSURGERY; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; METABOLISM; METHYLATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SURVIVAL; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; METHYLATION; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 77952549908     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.08.010     Document Type: Article

References (56)

1. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004, 22:2865-2872.
2. Cavaliere R., Schiff D. Cerebral metastases-a therapeutic update. Nat Clin Pract Neurol 2006, 2:426-436.
3. Ostermann S., Csajka C., Buclin T., Leyvraz S., Lejeune F., Decosterd L.A., et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004, 10:3728-3736.
4. Abrey L.E., Olson J.D., Raizer J.J., Mack M., Rodavitch A., Boutros D.Y., et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001, 53:259-265.
5. Christodoulou C., Bafaloukos D., Linardou H., Aravantinos G., Bamias A., Carina M., et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005, 71:61-65.
6. Giorgio C.G., Giuffrida D., Pappalardo A., Russo A., Santini D., Salice P., et al. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 2005, 50:247-254.
7. Addeo R., De Rosa C., Faiola V., Leo L., Cennamo G., Montella L., et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 2008, 113:2524-2531.
8. Addeo R., Caraglia M., Faiola V., Capasso E., Vincenzi B., Montella L., et al. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer 2007, 7:18.
9. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
10. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
11. Brell M., Tortosa A., Verger E., Gil J.M., Vinolas N., Villa S., et al. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 2005, 11:5167-5174.
12. Kulke M.H., Hornick J.L., Frauenhoffer C., Hooshmand S., Ryan D.P., Enzinger P.C., et al. O6-Methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009, 15:338-345.
13. Esteller M., Toyota M., Sanchez-Cespedes M., Capella G., Peinado M.A., Watkins D.N., et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000, 60:2368-2371.
14. Esteller M., Risques R.A., Toyota M., Capella G., Moreno V., Peinado M.A., et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001, 61:4689-4692.
15. Nakamura M., Watanabe T., Yonekawa Y., Kleihues P., Ohgaki H. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001, 22:1715-1719.
16. Wolf P., Hu Y.C., Doffek K., Sidransky D., Ahrendt S.A. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res 2001, 61:8113-8117.
17. Margison G.P., Povey A.C., Kaina B., Santibanez Koref M.F. Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis 2003, 24:625-635.
18. Fritz G., Tano K., Mitra S., Kaina B. Inducibility of the DNA repair gene encoding O6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments. Mol Cell Biol 1991, 11:4660-4668.
19. Costello J.F., Futscher B.W., Tano K., Graunke D.M., Pieper R.O. Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J Biol Chem 1994, 269:17228-17237.
20. Pegg A.E. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990, 50:6119-6129.
21. Esteller M., Hamilton S.R., Burger P.C., Baylin S.B., Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999, 59:793-797.
22. Rhee I., Bachman K.E., Park B.H., Jair K.W., Yen R.W., Schuebel K.E., et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416:552-556.
23. Rhee I., Jair K.W., Yen R.W., Lengauer C., Herman J.G., Kinzler K.W., et al. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000, 404:1003-1007.
24. McLendon R.E., Cleveland L., Pegram C., Bigner S.H., Bigner D.D., Friedman H.S. Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest 1998, 78:643-644.
25. Mattern J., Koomagi R., Volm M. Smoking-related increase of O6-methylguanine-DNA methyltransferase expression in human lung carcinomas. Carcinogenesis 1998, 19:1247-1250.
26. Mollemann M., Wolter M., Felsberg J., Collins V.P., Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005, 113:379-385.
27. Palmisano W.A., Divine K.K., Saccomanno G., Gilliland F.D., Baylin S.B., Herman J.G., et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000, 60:5954-5958.
28. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Blake C., Shibata D., et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000, 28:E32.
29. Ogino S., Kawasaki T., Brahmandam M., Cantor M., Kirkner G.J., Spiegelman D., et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006, 8:209-217.
30. Coleman W.B., Rivenbark A.G. Quantitative DNA methylation analysis: the promise of high-throughput epigenomic diagnostic testing in human neoplastic disease. J Mol Diagn 2006, 8:152-156.
31. Thomas A.J., Rock J.P., Johnson C.C., Weiss L., Jacobsen G., Rosenblum M.L. Survival of patients with synchronous brain metastases: an epidemiological study in southeastern Michigan. J Neurosurg 2000, 93:927-931.
32. Vecchi M., Confalonieri S., Nuciforo P., Vigano M.A., Capra M., Bianchi M., et al. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 2008, 27:2148-2158.
33. Wu J.M., Fackler M.J., Halushka M.K., Molavi D.W., Taylor M.E., Teo W.W., et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008, 14:1938-1946.
34. Citron M., Decker R., Chen S., Schneider S., Graver M., Kleynerman L., et al. O6-Methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res 1991, 51:4131-4134.
35. Nakasu S., Fukami T., Baba K., Matsuda M. Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 2004, 70:333-340.
36. Sasai K., Nodagashira M., Nishihara H., Aoyanagi E., Wang L., Katoh M., et al. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 2008, 32:1220-1227.
37. Hegi M.E., Liu L., Herman J.G., Stupp R., Wick W., Weller M., et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008, 26:4189-4199.
38. Yanagawa R., Furukawa Y., Tsunoda T., Kitahara O., Kameyama M., Murata K., et al. Genome-wide screening of genes showing altered expression in liver metastases of human colorectal cancers by cDNA microarray. Neoplasia 2001, 3:395-401.
39. Hao X., Sun B., Hu L., Lahdesmaki H., Dunmire V., Feng Y., et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 2004, 100:1110-1122.
40. Albanese I., Scibetta A.G., Migliavacca M., Russo A., Bazan V., Tomasino R.M., et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 2004, 325:784-791.
41. Park T.J., Han S.U., Cho Y.K., Paik W.K., Kim Y.B., Lim I.K. Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer 2001, 92:2760-2768.
42. Smith-Sorensen B., Lind G.E., Skotheim R.I., Fossa S.D., Fodstad O., Stenwig A.E., et al. Frequent promoter hypermethylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene in testicular cancer. Oncogene 2002, 21:8878-8884.
43. Baeza N., Weller M., Yonekawa Y., Kleihues P., Ohgaki H. PTEN methylation and expression in glioblastomas. Acta Neuropathol 2003, 106:479-485.
44. Lenz G., Hutter G., Hiddemann W., Dreyling M. Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia. Ann Hematol 2004, 83:628-633.
45. Lavon I., Fuchs D., Zrihan D., Efroni G., Zelikovitch B., Fellig Y., et al. Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. Cancer Res 2007, 67:8952-8959.
46. Silber J.R., Bobola M.S., Ghatan S., Blank A., Kolstoe D.D., Berger M.S. O6-Methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 1998, 58:1068-1073.
47. Esteller M., Gaidano G., Goodman S.N., Zagonel V., Capello D., Botto B., et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 2002, 94:26-32.
48. Ohno T., Hiraga J., Ohashi H., Sugisaki C., Li E., Asano H., et al. Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma. Int J Hematol 2006, 83:341-347.
49. Shen L., Kondo Y., Rosner G.L., Xiao L., Hernandez N.S., Vilaythong J., et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005, 97:1330-1338.
50. Marsit C.J., Houseman E.A., Christensen B.C., Eddy K., Bueno R., Sugarbaker D.J., et al. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 2006, 66:10621-10629.
51. Liu Y., Lan Q., Siegfried J.M., Luketich J.D., Keohavong P. Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 2006, 8:46-51.
52. Safar A.M., Spencer H., Su X., Coffey M., Cooney C.A., Ratnasinghe L.D., et al. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 2005, 11:4400-4405.
53. Toyooka S., Maruyama R., Toyooka K.O., McLerran D., Feng Z., Fukuyama Y., et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003, 103:153-160.
54. Gaspar L., Scott C., Rotman M., Asbell S., Phillips T., Wasserman T., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745-751.
55. Bae S.I., Lee H.S., Kim S.H., Kim W.H. Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers. Br J Cancer 2002, 86:1888-1892.
56. Baumann S., Keller G., Puhringer F., Napieralski R., Feith M., Langer R., et al. The prognostic impact of O6-methylguanine-DNA methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma. Int J Cancer 2006, 119:264-268.